Herbert Loong: Join us at ESMO24 to discuss the emerging role of ADCs

Herbert Loong shared on LinkedIn:

“Heading to Barcelona for ESMO24?

Come join us on Saturday evening as we discuss the emerging role of Antibody Drug Conjugates (ADCs) in the treatment of NSCLC.”

Source: Herbert Loong/LinkedIn

More posts featuring Herbert Loong on oncodaily.com

Dr. Herbert H. F. Loong holds several prominent positions in oncology. He is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO). Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network.

Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).